CENTOGENE to Participate in Upcoming Partnering Conferences in October
October 06 2022 - 06:00AM
Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential
biodata life science partner for rare and neurodegenerative
diseases, today announced its partnering conference schedule for
October 2022. Company management and the business development team
will be attending events in the U.K. and Germany. CENTOGENE invites
partners to schedule one-on-one meetings.
Please see additional details below:
European Society of Gene & Cell Therapy
(ESGCT) Annual Congress |
|
Dates: |
October 11-14,
2022 |
|
Location: |
Edinburgh International Conference Centre (EICC), U.K. |
|
Format: |
One-on-one meetings |
|
|
|
|
To learn more about the ESGCT Annual Congress,
please visit the event website (https://www.esgctcongress.com/). To
set up a one-on-one meeting with the CENTOGENE team, contact
BD@centogene.com. |
|
|
|
BIO-Europe® |
|
Dates: |
October 24-26, 2022 |
|
Location: |
Leipzig Messe, Germany / Virtual |
|
Format: |
Presentation, one-on-one meetings |
|
Presentation: |
CENTOGENE Digital Company Presentation |
|
Speaker: |
Kim Stratton, CENTOGENE CEO |
|
|
|
|
For information about BIO-Europe, please visit the
event website (https://informaconnect.com/bioeurope/). Book an
in-person or virtual meeting directly with CENTOGENE in
advance by contacting BD@centogene.com, or via the PartneringONE®
Platform. |
About CENTOGENE
CENTOGENE (Nasdaq: CNTG) is transforming real-world clinical,
genetic, and multiomic data to enable better health outcomes for
patients with rare and neurodegenerative diseases. For over 15
years, CENTOGENE has been providing diagnostic insights to patients
with genetic diseases through our network of nearly 30,000 active
physicians. CENTOGENE now believes its Biodatabank is the world’s
largest real-world data repository of corresponding patients from
more than 120 countries. Simplified logistics solutions, including
CentoCard® for sending biosamples, and our ISO, CAP, & CLIA
certified state-of-the-art multiomic reference labs offer patients
rapid and reliable diagnoses to support the identification and
personalization of their treatments. Ultimately, offering the best
treatment for patients involves developing new or better therapies.
We are de-risking orphan drug discovery and development by
partnering with more than 30 biopharma in target & drug
screening, clinical development, market access and expansion.
CENTOGENE engages in biodata partnerships with our Biodata Licenses
and Insight Reports.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us
on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth and enter into new client relationships,
our dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates, our ability
to streamline cash usage, our requirement for additional financing,
or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on March 31, 2022,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media Contact:CENTOGENELennart
Streibel Investor
Relations Investor.Relations@centogene.com
Ben Legg Corporate
Communications Press@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Feb 2024 to Mar 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Mar 2023 to Mar 2024